about
Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicinManagement of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center.Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients.Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.Dasatinib first-line: Multicentric Italian experience outside clinical trials.Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance.A long-term study of young patients with essential thrombocythemia treated with anagrelide.Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians.Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML).Early and late complications related to central venous catheters in hematological malignancies: a retrospective analysis of 1102 patients.The risk of infections in patients with myelodysplastic syndromes in 2016.Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.Management of acute promyelocytic leukemia in the elderly."Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia.Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia.Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN.Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC).Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response.Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase.Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation.FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis.Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up.Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry.Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results.Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols.Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem.
P50
Q28298296-D4D48E85-491A-4A8F-B095-66018D83C129Q30400820-080EB64B-9480-4481-B40B-7F98B86674F5Q33388797-A1317275-BA1D-4914-851F-0EB5E4B23D00Q33392434-40ACEC2E-10F4-4F39-A0B7-59A904112E71Q33428221-6217B2FE-9866-46EE-9B3F-EF0383FEEFD2Q33437121-02E80002-0A6B-4C1A-AECA-9D61ABA0D4E0Q33439015-4179AB64-18DD-4D3A-9648-CB63F28ECC47Q33441917-954C1C9F-7E31-4A91-8B3E-59A2BBDA504AQ33775211-B968E45F-F87E-4E8F-B36F-16AE81517CD4Q34169298-A2796470-116F-40D7-96F8-D1FDAD29E07CQ34552490-B9D10259-E4CA-4E3D-8DDA-796A7627B0A1Q34890434-D288BD86-D5D8-4846-9865-FAB13DF3C018Q35265868-46D49DDB-1558-42CB-9567-8B614A87AEE5Q35944724-CB5A5098-B72B-453A-8A63-697340235034Q37273788-35494FF2-6000-4780-9189-AEE04B399DFDQ38138480-4EC05D74-9CCA-4055-AAA8-491F10D2DAD1Q38510120-E03C6141-690E-4C4F-B140-E59C46A20735Q38813702-5BE0B29B-6A7C-4054-93E5-C1352BE337D4Q38814941-B023DD02-1525-4A29-9D67-72214DD66D6BQ39368616-3B7BAA0D-51E5-4B8A-AE65-48664BF8C709Q39847714-521974B0-B4BF-49C9-9D71-0BDAFD05A026Q40125614-DCC5BB25-C954-4DB2-A508-5C7DF0CCBD55Q40231203-9075551F-21BC-46C1-A394-E764EEC36AB1Q40460173-C0EE7ED4-D324-47D2-9EE2-65F3464180E9Q40639096-F2EA0644-9983-4DE7-AE7A-A27BABFD82FDQ40845072-32A79A2E-54D5-4842-B2ED-6B9B6B46C5A8Q41288101-9936C0CB-F079-4AB8-8D56-BFF525B0D1E1Q41724361-EE33C5AF-7D0F-4902-A51D-8B30C39AA8F3Q42276725-393A3ACC-33E0-4A91-91F3-CCE8473D028AQ42316987-FE4C231A-7AAF-43D1-A2A7-B2B30EEBE619Q42768186-EF747346-0E55-4965-A21F-CD8DB7DAF817Q42831333-15DF92FC-A344-4224-8764-3CF16A5154E7Q43057273-C02C69AD-1C75-43B4-9895-346B2D376B1BQ43122342-913FDE1C-0E4E-4C16-8E08-6A8C830A0BD6Q43281441-F9B7BB0F-F10C-4721-9496-75B9FBC992AAQ43286531-CF1E1494-12B7-40E0-9A17-53A3CF9AE885Q43287371-C236011D-89E2-4F6F-8EB3-079726867DC5Q43475684-0EAA555C-970E-4A52-B199-F421DB720D18Q43783174-339EE538-EF32-4A8B-B0FE-D746A94C3BB3Q43863897-92E95FD1-9D96-478B-9389-CF610719C895
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Roberto Latagliata
@ast
Roberto Latagliata
@en
Roberto Latagliata
@es
Roberto Latagliata
@nl
type
label
Roberto Latagliata
@ast
Roberto Latagliata
@en
Roberto Latagliata
@es
Roberto Latagliata
@nl
prefLabel
Roberto Latagliata
@ast
Roberto Latagliata
@en
Roberto Latagliata
@es
Roberto Latagliata
@nl
P106
P21
P31
P496
0000-0002-7741-862X